Exemestane and Ketoconazole Interaction: Monitor | Peptide Database

Join others researching Minoxidil — share findings, ask questions, and learn from real experiences Minoxidil is an FDA-approved vasodilator originally developed in the 1970s as an oral antihypertensive medication. Its hair growth properties were discovered as a side effect, and topical formulations (2% and 5%) were subsequently approved for the treatment of androgenetic alopecia. It remains one of only two FDA-approved treatments for pattern hair loss and is available over the counter in most countries. In recent years, off-label oral minoxidil at low doses (0.625-5mg) has gained significant traction among dermatologists and the biohacker community as a more convenient and potentially more effective alternative to topical application, particularly for individuals who find the topical formulation inconvenient or who experience scalp irritation. Minoxidil is a potassium channel opener that acts on ATP-sensitive potassium channels in vascular smooth muscle cells, causing vasodilation. When applied topically or taken orally, it is converted to its active metabolite minoxidil sulfate by the enzyme sulfotransferase (SULT1A1) in hair follicle outer root sheath cells. The sulfated form opens potassium channels in dermal papilla cells and vascular smooth muscle surrounding hair follicles, increasing local blood flow and nutrient delivery. Beyond vasodilation, minoxidil upregulates vascular endothelial growth factor (VEGF) expression, extends the anagen (growth) phase of the hair cycle, increases follicle size, and stimulates the transition of resting follicles from telogen into anagen. It also has anti-fibrotic properties that may benefit the perifollicular environment. Notably, minoxidil's hair growth effects are androgen-independent, making it effective regardless of DHT levels and complementary to 5-alpha reductase inhibitors like finasteride.

VIP inhalation shows striking efficacy with increased mixed venous oxygen saturation and exercise capacity. Dilates peripheral blood vessels through NO-dependent mechanisms above 100 pmol doses. Coronary vasodilation with positive inotropic and chronotropic effects on the heart. Promising therapeutic target for Alzheimer's, Parkinson's, and other neurological disorders. Potential therapeutic target being researched for ASD. Produced in suprachiasmatic nuclei; involved in circadian regulation. Promotes insulin secretion in glucose-dependent manner via VPAC2; low hypoglycemia risk. Potent anti-inflammatory effects useful in IBD and autoimmune conditions. Therapeutic potential for pulmonary and systemic sarcoidosis.